文献速递白血病

血清Flt3配体是急性髓系白血病祖细胞负荷与预后的生物标志物

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2019-01-01

本研究探讨血清Flt3配体(Flt3L)在急性髓系白血病(AML)中的临床意义。Flt3L在骨髓增生低下时升高,而Flt3+ AML时降至不可测。诱导化疗后完全缓解者Flt3L恢复,难治者持续低。UK NCRI AML17试验中140例Flt3突变患者第26天Flt3L与完全缓解及生存相关,联合MRD可增强预后区分。系列监测有助于识别移植后复发。

要点

  • Flt3L在Flt3+ AML中降至不可测,化疗后完全缓解者恢复。
  • 第26天Flt3L≤291 pg/mL与较差无事件生存相关。

核心结论

  • 血清Flt3L是无创生物标志物,可反映AML祖细胞负荷并辅助预后判断。

研究设计与样本

  • UK NCRI AML17试验中,140例Flt3突变AML患者随机接受lestaurtinib或安慰剂,第26天测Flt3L。
  • 系列采样观察治疗前6周Flt3L动力学,并分析移植后监测价值。

主要发现

  • 达到完全缓解者第26天Flt3L较高(Mann-Whitney UP<.0001)。
  • 第26天Flt3L≤291 pg/mL与较差无事件生存相关。
  • 第26天Flt3L>1185 pg/mL与较高总生存相关(P=.0119)。
  • Flt3L联合MRD状态可增强EFS和OS曲线的分离。
  • 移植后系列监测Flt3L可能有助于识别复发。

关键数值与推荐

  • 第26天Flt3L≤291 pg/mL提示无事件生存较差。
  • 第26天Flt3L>1185 pg/mL提示总生存较高(P=.0119)。

临床怎么用

  • 可考虑在AML诱导化疗后第26天检测Flt3L辅助评估缓解与预后。
  • Flt3L联合MRD可能优化风险分层。
  • 移植后系列监测Flt3L或有助于早期发现复发。

局限性

  • Flt3L分析仅限140例Flt3突变患者亚组。
  • 校正文中未报告多变量模型的具体结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fms-like tyrosine kinase 3 (Flt3) is expressed on progenitor cells and acute myeloid leukemia (AML) blasts. Fms-like tyrosine kinase 3 ligand (Flt3L) is detectable during homeostasis and increases in hypoplasia due to genetic defects or treatment with cytoreductive agents. Conversely, Flt3+ AML is associated with depletion of Flt3L to undetectable levels. After induction chemotherapy, Flt3L is restored in patients entering complete remission (CR) but remains depressed in those with refractory disease. Weekly sampling reveals marked differences in the kinetics of Flt3L response during the first 6 weeks of treatment, proportionate to the clearance of blasts and cellularity of the bone marrow. In the UK NCRI AML17 trial, Flt3L was measured at day 26 in a subgroup of 140 patients with Flt3 mutation randomized to the tyrosine kinase inhibitor lestaurtinib or placebo. In these patients, attainment of CR was associated with higher Flt3L at day 26 (Mann-Whitney UP < .0001). Day 26 Flt3L was also associated with survival; Flt3L ≤291 pg/mL was associated with inferior event-free survival (EFS), and Flt3L >1185 pg/mL was associated with higher overall survival (OS; P = .0119). The separation of EFS and OS curves increased when minimal residual disease (MRD) status was combined with Flt3L measurement, and Flt3L retained a near-significant association with survival after adjusting for MRD in a proportional hazards model. Serial measurement of Flt3L in patients who had received a hematopoietic stem cell transplant for AML illustrates the potential value of monitoring Flt3L to identify relapse. Measurement of Flt3L is a noninvasive test with the potential to inform clinical decisions in patients with AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Milne P, Wilhelm-Benartzi C, Grunwald MR, et al. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Adv. 2019. PMID: 31648336. doi:10.1182/bloodadvances.2019000197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。